A small case-control study linked higher Dietary Inflammatory Index scores with progressive vitiligo, suggesting that ...
In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions: In ‘A Milestone in Vitiligo: Clinical Efficacy ...
Clinuvel is tipped to release phase III trial results for the skin disorder vitiligo - the 'Michael Jackson disease' - within months ...
Zacks Small Cap Research on MSN
EDSA: Preparing for mid-2026 start to phase 2 vitiligo trial
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Vitiligo Trial to Initiate in Mid-2026 ...
Around one in every 100 people worldwide has vitiligo – a chronic, autoimmune skin condition that causes the skin to appear ...
Nearly one-third of patients diagnosed with vitiligo go untreated after their diagnosis, and those who did receive care cycle ...
With better screening for type 1 diabetes and a new treatment called TZield, the outlook is improving for people with the ...
(“STRATA” or the “Company”), a global leader in excimer laser therapy dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today ...
A new cream offering hope to over 80,000 people in England living with vitiligo has been approved for NHS use. Ruxolitinib, sold under the brand name Opzelura, is the first licensed treatment to ...
In both studies, upadacitinib met the coprimary endpoints of T-VASI 50 and F-VASI 75 at week 48 vs placebo. Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in ...
Adding twice-weekly narrowband UVB phototherapy to oral ritlecitinib may enhance response to treatment of nonsegmental vitiligo. Dual treatment was well-tolerated with no new safety signals in this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results